Previous reports show that, in several melanoma cells, expression of differentiation antigens (Tyrosinase, Melan-A or CSPG4) increased after short-term treatment with BRAFi followed by a decrease at long-term, affecting T cell recognition (Pieper et al., 2018; Harbers et al., 2021). This evidence concerns the gene CSPG4 and melanoma.